Previous close | 7.30 |
Open | 9.52 |
Bid | 8.80 |
Ask | 10.70 |
Strike | 360.00 |
Expiry date | 2025-01-17 |
Day's range | 9.52 - 9.52 |
Contract range | N/A |
Volume | |
Open interest | 70 |
In a recent forecast, BMO Capital Markets has predicted the global market for innovative weight-loss drugs, such as Novo Nordisk (NYSE:NVO) A/S's Ozempic and Wegovy, to reach $100 billion by 2035. This projection follows an increase in patient recognition of the efficacy of these medications.
Based on analysts' projections, you might think the pharmaceutical giant isn't worth investing in right now.
Eli Lilly, Toyota Motor, Accenture, The Walt Disney and CVS Health are part of the Zacks top Analyst Blog.